Across TCGA pan-cancer cohorts, MIR125B2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MIR125B2 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher MIR125B2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR125B2 expression acts as an unfavorable survival marker.

LUSC and SKCM are the cancer types where MIR125B2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.196	0.776	.006	24	view →
SKCM	DFS	Median	All	0.228	0.738	.002	19	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MIR125B2 tumor-vs-normal RNA expression · all MIR125B2 data types